X

Drug Profile

PRT 120

Alternative Names: PRT-120

Latest Information Update: 20 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Prota Therapeutics
Developer Murdoch Childrens Research Institute; Prota Therapeutics
Class Allergens; Antiallergics; Food allergy immunotherapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Peanut hypersensitivity

Most Recent Events

14 Aug 2024 Efficacy data from a phase II trial in Peanut hypersensitivity released by Prota Therapeutics
16 Jan 2024 Prota Therapeutics plans to files an IND application for Peanut hypersensitivity
16 Jan 2024 Prota Therapeutics plans a phase III trial for Peanut hypersensitivity

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com